uniQure (NASDAQ:QURE) Upgraded at StockNews.com

StockNews.com upgraded shares of uniQure (NASDAQ:QURE) to a sell rating in a research note issued to investors on Thursday morning.

QURE has been the topic of a number of other research reports. Raymond James reaffirmed an “outperform” rating and issued a $20.00 target price on shares of uniQure in a report on Thursday, October 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $28.00 target price on shares of uniQure in a report on Friday, September 20th. The Goldman Sachs Group lifted their price objective on uniQure from $6.00 to $10.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. Finally, HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of uniQure in a report on Tuesday, August 20th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $19.50.

uniQure Stock Performance

QURE opened at $6.42 on Thursday. The firm has a market capitalization of $311.68 million, a P/E ratio of -1.03 and a beta of 0.95. The stock’s 50 day moving average price is $5.77 and its two-hundred day moving average price is $5.67. The company has a quick ratio of 7.36, a current ratio of 7.36 and a debt-to-equity ratio of 1.06. uniQure has a 12-month low of $3.73 and a 12-month high of $11.35.

uniQure (NASDAQ:QURE) last released its earnings results on Thursday, August 1st. The biotechnology company reported ($1.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.24) by $0.08. The firm had revenue of $11.13 million for the quarter, compared to analyst estimates of $3.47 million. uniQure had a negative return on equity of 158.09% and a negative net margin of 1,027.52%. On average, equities analysts forecast that uniQure will post -4.1 earnings per share for the current year.

Institutional Trading of uniQure

Several institutional investors have recently modified their holdings of the company. Vanguard Personalized Indexing Management LLC boosted its stake in uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 2,306 shares in the last quarter. Total Clarity Wealth Management Inc. acquired a new stake in uniQure in the 2nd quarter valued at $74,000. SG Americas Securities LLC acquired a new stake in uniQure in the 2nd quarter valued at $79,000. Cubist Systematic Strategies LLC boosted its stake in uniQure by 130.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 25,494 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 14,454 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in uniQure in the 2nd quarter valued at $175,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.